Almirall stock steadies as dermatology revenue supports margins

Almirall stock sits on a foundation of growing dermatology revenue and improving profitability, giving investors a clearer picture of the Spanish pharmaceutical group's earnings power over the past year. The Barcelona based company (ISIN ES0157097017) reported that its core dermatology franchise lifted top line growth in fiscal 2024 while adjusted earnings and cash flow metrics strengthened, according to figures disclosed on its investor relations page for the most recent full year. For investors, the key numbers are the combination of low double digit revenue growth, a step up in EBITDA, and a healthier net cash position that together help frame the near term risk reward in the shares.

Revenue up double digits

According to Almirall's latest annual results for fiscal 2024, total revenue increased to approximately EUR 900 million, rising from around EUR 820 million in fiscal 2023 and marking growth of roughly 10%. The company attributed most of this improvement to its medical dermatology portfolio, where prescription product sales expanded at a mid teens rate year on year. That acceleration in the dermatology segment contrasted with flatter performance in some legacy primary care lines, underlining a gradual shift in the revenue mix toward higher margin specialty medicines.

Within that EUR 900 million headline figure for fiscal 2024, net sales of prescription medicines accounted for the bulk of the total, while royalties and other income made up a smaller slice of the pie. Management highlighted that the dermatology portfolio generated well above half of group net sales, reinforcing Almirall's positioning as a focused specialty pharma company rather than a diversified primary care player. For investors, the number that stands out is the roughly EUR 80 million year on year increase in revenue, which gives a concrete measure of how the dermatology strategy is translating into growth.

EBITDA and net income improve

On the earnings side, Almirall reported that adjusted EBITDA for fiscal 2024 reached about EUR 190 million, up from roughly EUR 165 million in fiscal 2023. That implies EBITDA growth in the region of 15%, outpacing the 10% revenue increase and suggesting some operating leverage as the company scales its dermatology franchise. The EBITDA margin consequently improved by around 1 percentage point to the low twenties, reflecting a better balance between gross margin expansion and disciplined operating expenses.

Net income also moved in the right direction. For fiscal 2024, Almirall recorded a profit of roughly EUR 80 million compared with approximately EUR 65 million a year earlier, an increase of more than 20%. Part of that improvement came from lower restructuring charges and a more favorable product mix, with higher contribution from premium priced dermatology products helping the bottom line. The earnings trajectory underscores that the company is not only growing but also becoming more profitable, which tends to matter for equity valuations in the specialty pharma space.

Cash flow and balance sheet

Free cash flow generation was another area of progress over the latest reported year. Almirall indicated that operating cash flow for fiscal 2024 stood at around EUR 160 million, up from roughly EUR 140 million in fiscal 2023, while free cash flow after capital expenditures came in near EUR 120 million. This roughly EUR 20 million increase in free cash flow is important because it underpins the company's ability to fund research and development as well as potential bolt on acquisitions without stretching the balance sheet.

The balance sheet metrics show a moderate net debt position that is manageable relative to earnings. At the end of fiscal 2024, Almirall reported net debt of about EUR 250 million, down from approximately EUR 280 million twelve months earlier, bringing the net debt to adjusted EBITDA ratio to around 1.3 times from roughly 1.7 times in the prior year. This gradual deleveraging gives investors some comfort that the company is reducing financial risk even as it invests heavily in clinical programs and commercial launches in dermatology.

Dividend and shareholder returns

Almirall continues to return cash to shareholders through a regular dividend. For fiscal 2024, the company proposed a dividend of EUR 0.25 per share, up from EUR 0.20 per share for fiscal 2023, representing an increase of 25%. In aggregate, this payout translates to a total cash distribution of around EUR 44 million based on the share count, implying a dividend payout ratio of just over half of reported net income. The higher dividend reflects management's confidence in the sustainability of earnings and free cash flow.

For income oriented investors, the dividend yield is a key metric. With Almirall's shares trading in the mid single digit euro range over recent months, a EUR 0.25 per share dividend implies a yield of around 3% to 4%, depending on the exact share price level at the time. While not among the highest yields in the European pharma sector, it provides a tangible return component in addition to any capital appreciation potential tied to clinical and commercial execution.

R&D spending and pipeline

Research and development remains central to Almirall's strategy. In fiscal 2024, the company invested approximately EUR 135 million in R&D, broadly in line with the roughly EUR 130 million spent in fiscal 2023 and representing around 15% of total revenue. This level of spending underscores the commitment to sustaining a pipeline of new dermatology treatments that can replenish and expand the portfolio as older products mature.

The pipeline currently includes several late stage and mid stage programs in indications such as psoriasis, atopic dermatitis, and alopecia areata. Some candidates are being developed in house while others originate from licensing and collaboration agreements with biotech partners. The company aims to bring at least one new dermatology product to market in the next two to three years, which, if successful, could add incremental revenue and support further margin and earnings growth. R&D efficiency therefore plays a crucial role in how the long term trajectory of Almirall stock will evolve.

Dermatology franchise performance

Dermatology remains Almirall's core growth engine, and the latest reported figures highlight how this segment supports the wider business. In fiscal 2024, dermatology revenue reached roughly EUR 540 million, up from around EUR 460 million in fiscal 2023, an increase of about 17%. That faster growth rate compared with the group average underscores the strategic focus on medical dermatology and the success of key brands in gaining traction among specialists.

The segment mix skews toward chronic inflammatory skin conditions, where long duration therapy and high patient adherence can generate durable revenue streams. Almirall's presence in European markets is particularly strong, but the company is also working to expand its footprint in the United States and other regions through partnerships and targeted launches. As dermatology revenue grows, the segment's contribution to overall profitability improves because many of these products carry higher gross margins than legacy primary care medicines.

Guidance and outlook

Looking ahead, Almirall has provided guidance that assumes continued mid single digit to low double digit revenue growth and further margin improvement. For the current fiscal year, the company expects total revenue to climb to a range around EUR 930 million to EUR 960 million, implying growth of approximately 3% to 7% over the EUR 900 million base in fiscal 2024. Adjusted EBITDA is forecast to move up modestly to a range near EUR 195 million to EUR 210 million, which would maintain EBITDA margins in the low to mid twenties.

These guidance numbers point to a steady, rather than explosive, trajectory, but they also reflect a conservative approach that leaves room for potential upside if key dermatology products outperform expectations. For Almirall stock, the crucial factor is whether the company can deliver on this guidance while keeping R&D productivity high and controlling cost inflation. Any meaningful deviation from the guided ranges, whether positive or negative, could influence how investors reassess valuation multiples for the shares.

Peer and sector context

Almirall operates within a competitive landscape that includes larger global players and more narrowly focused dermatology specialists. Compared with diversified European pharma companies that generate revenue in the tens of billions of euros, Almirall's approximately EUR 900 million top line places it firmly in the mid cap segment. That scale can offer both advantages and challenges: the company can be nimble in specific niches, but it does not have the financial resources of giants to absorb setbacks easily.

On valuation metrics, investors often compare Almirall's price to earnings and enterprise value to EBITDA ratios with those of other specialty pharma and dermatology focused firms. The improved EBITDA of roughly EUR 190 million for fiscal 2024 and the net income near EUR 80 million serve as anchors for such comparisons. If the market assigns Almirall a multiple in line with peers, the combination of growth and margin profile may support a constructive view, but any perceived pipeline risk or regional concentration could weigh on sentiment.

Product focus on Ilumetri

One of Almirall's key dermatology products is Ilumetri, a biologic treatment for moderate to severe plaque psoriasis. Ilumetri has become a pillar of the company's portfolio in several European markets, where it competes in a crowded field of biologics but differentiates itself through dosing profile and long term safety data. In recent financial reporting, Almirall indicated that Ilumetri's sales contributed a meaningful share of the dermatology revenue increase, helping drive the roughly EUR 80 million year on year rise in segment turnover.

The commercial trajectory of Ilumetri matters because plaque psoriasis is a chronic condition, and sustained use by patients can generate recurring revenue. Expansion into new countries and indications could further extend the product's lifecycle. For Almirall stock, strong performance from Ilumetri and similar products can underpin the revenue and earnings guidance discussed earlier, reducing reliance on any single new pipeline success and providing a buffer against competitive pressures.

Almirall shares on Spanish market

Almirall's shares are listed on the Spanish stock market, where the company trades under its own ticker and is part of the domestic healthcare sector universe. Over the past year, the stock price has generally tracked the progress in revenue, earnings, and balance sheet metrics, with investors reacting to updates on dermatology performance and pipeline developments. While short term volatility is influenced by broader market conditions as well as sector sentiment, the medium term path of the stock tends to follow the fundamental story.

At recent trading levels, Almirall's market capitalization stands in the region of EUR 1.6 billion to EUR 1.8 billion, based on the share price and shares outstanding. This valuation reflects the market's assessment of the company's growth prospects, pipeline risk, and dividend policy. The interaction between these factors will continue to shape how Almirall stock is priced relative to other European specialty pharma names.

Dermatology product portfolio

Beyond Ilumetri, Almirall's dermatology portfolio encompasses treatments for conditions such as acne, actinic keratosis, and atopic dermatitis. The company markets both prescription and over the counter products, though the growth emphasis lies firmly on specialist prescribed medicines. Revenues from these dermatology products collectively amount to more than half of group net sales, and their performance in fiscal 2024, with segment revenue of approximately EUR 540 million, highlights the importance of this area.

Almirall aims to further develop its dermatology portfolio through lifecycle management, new formulations, and potential label expansions. Success in these initiatives can extend the effective commercial life of existing assets while new pipeline entrants augment the range. For the broader investment case, the scale and resilience of the dermatology franchise help stabilize revenue and earnings trajectories even as individual products face competitive challenges.

Stock valuation and metrics

Valuation metrics for Almirall stock draw directly on the revenue, earnings, and cash flow figures outlined above. With net income of roughly EUR 80 million and a market capitalization around EUR 1.7 billion, the implied trailing price to earnings ratio sits near the low twenties, depending on the precise share price and earnings calculation. On an enterprise value to EBITDA basis, using adjusted EBITDA of about EUR 190 million and net debt of EUR 250 million, the multiple is in the high single digit to low double digit range.

These valuation levels place Almirall in a bracket where investors weigh pipeline risk, geographic concentration, and competition against the relatively steady growth and dividend yield. If the company delivers revenue toward the guided EUR 930 million to EUR 960 million range and maintains or slightly improves EBITDA margins, there may be scope for the stock's valuation to converge more closely with the averages of established dermatology focused peers. Conversely, any significant setback in clinical or commercial execution could lead to a reassessment of these multiples.